首页> 美国卫生研究院文献>Oncotarget >Antitumor activity and inhibitory effects on cancer stem cell-like properties of Adeno-associated virus (AAV) -mediated Bmi-1 interference driven by Bmi-1 promoter for gastric cancer
【2h】

Antitumor activity and inhibitory effects on cancer stem cell-like properties of Adeno-associated virus (AAV) -mediated Bmi-1 interference driven by Bmi-1 promoter for gastric cancer

机译:Bmi-1启动子驱动的腺相关病毒(AAV)介导的Bmi-1干扰的抗肿瘤活性及其对癌干细胞样特性的抑制作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Bmi-1 is aberrantly activated in various cancers and plays a vital role in maintaining the self-renewal of stem cells. Our previous research revealed that Bmi-1 was overexpressed in gastric cancer (GC) and it's overexpression was an independent negative prognostic factor, suggesting it can be a therapeutic target. The main purpose of this investigation was to explore the antitumor activity of Bmi-1 interference driven by its own promoter (Ad-Bmi-1i) for GC. In this study, we used adenoviral vector to deliver Bmi-1 shRNA driven by its own promoter to treat GC. Our results revealed that Ad-Bmi-1i could selectively silence Bmi-1 in GC cells which overexpress Bmi-1 and suppress the malignant phenotypes and stem-like properties of GC cells in vitro and in vivo. Moreover, direct injection of Ad-Bmi-1i into xenografts suppressed tumor growth and destroyed cancer cells in vivo. Ad-Bmi-1i inhibited the proliferation of GC cells mainly via inducing senescence in vitro, but it suppressed tumor through inducing senescence and apoptosis, and inhibiting angiogenesis in vivo. Bmi-1 knockdown by Ad-Bmi-1i downregulated VEGF via inhibiting AKT activity. These results suggest that Ad-Bmi-1i not only inhibits tumor growth and stem cell-like phenotype by inducing cellular senescence directly, but also has an indirect anti-tumor activity by anti-angiogenesis effects via regulating PTEN/AKT/VEGF pathway. Transfer of gene interference guided by its own promoter by an adeno-associated virus (AAV) vector might be a potent antitumor approach for cancer therapy.
机译:Bmi-1在各种癌症中均被异常激活,并且在维持干细胞的自我更新中起着至关重要的作用。我们以前的研究表明,Bmi-1在胃癌(GC)中过表达,并且过表达是一个独立的阴性预后因素,表明它可以作为治疗靶标。这项研究的主要目的是探讨由其自身的启动子(Ad-Bmi-1i)驱动的Bmi-1干扰素对GC的抗肿瘤活性。在这项研究中,我们使用腺病毒载体递送由其自身启动子驱动的Bmi-1 shRNA来治疗GC。我们的结果表明,Ad-Bmi-1i可以选择性沉默沉默过表达Bmi-1的GC细胞中的Bmi-1,并在体内外抑制GC细胞的恶性表型和干样特性。此外,将Ad-Bmi-1i直接注射到异种移植物中可抑制肿瘤生长并在体内破坏癌细胞。 Ad-Bmi-1i主要通过体外诱导衰老来抑制GC细胞的增殖,但通过诱导衰老和凋亡并在体内抑制血管生成来抑制肿瘤。 Ad-Bmi-1i对Bmi-1的抑制作用通过抑制AKT活性而下调VEGF。这些结果表明,Ad-Bmi-1i不仅通过直接诱导细胞衰老来抑制肿瘤生长和干细胞样表型,而且还通过调节PTEN / AKT / VEGF途径的抗血管生成作用而具有间接的抗肿瘤活性。腺相关病毒(AAV)载体在其自身启动子的指导下转移基因干扰可能是用于癌症治疗的有效抗肿瘤方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号